Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of
one ligand that binds to a protein of interest (POI) and another that can recruit an E3 …

RNA adopts 3D structures that confer varied functional roles in human biology and
dysfunction in disease. Approaches to therapeutically target RNA structures with small …

Target occupancy is often insufficient to elicit biological activity, particularly for RNA,
compounded by the longstanding challenges surrounding the molecular recognition of RNA …

Many diseases are caused by insufficient expression of mutated genes and would benefit
from increased expression of the corresponding protein. However, in drug development, it …

Ribonuclease targeting chimeras (RiboTACs) induce degradation of an RNA target by
facilitating an interaction between an RNA and a ribonuclease (RNase). We describe the …

Nature has evolved intricate machinery to target and degrade RNA, and some of these
molecular mechanisms can be adapted for therapeutic use. Small interfering RNAs and …

Targeted protein degradation (TPD), represented by proteolysis-targeting chimera
(PROTAC), has emerged as a novel therapeutic modality in drug discovery. However, the …

The interactions between cellular RNAs in MDA-MB-231 triple negative breast cancer cells
and a panel of small molecules appended with a diazirine cross-linking moiety and an …

Targeted protein degradation technology has evolved a brand-new therapeutic modality
from an innovative drug discovery perspective. Though the classical PROTACs has …

Cancer is a global public health concern. Alterations in epigenetic processes are among the
earliest genomic aberrations occurring during cancer development and are closely related …